Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2025-04-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding changes in accounting policies by the company Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It references new accounting standards issued by the Ministry of Finance of the People's Republic of China and explains the impact of these changes on the company's financial statements. The document does not contain actual financial statements or detailed financial data but rather informs about the policy changes and their expected effects. It is not a full annual or interim report, nor is it a certification or a regulatory filing of another type. The document is a formal announcement about accounting policy changes, which fits best under Regulatory Filings (RNS) as it does not meet the criteria for other more specific categories.
2025-04-23 Chinese
舆情管理制度
Governance Information Classification · 95% confidence The document is titled '舆情管理制度' which translates to 'Public Opinion Management System' or 'Crisis Management Policy' for the company 上海泓博智源医药股份有限公司. It outlines internal policies and procedures for managing public opinion, media relations, and crisis response related to the company. There is no financial data, no mention of financial results, no regulatory filings or voting results, no management changes, no capital updates, no earnings information, no legal proceedings, no merger or acquisition activity, and no shareholder transactions. The document is a governance-related internal policy document approved by the board, focusing on organizational and procedural rules for managing public opinion and information disclosure. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 2908 characters, which is relatively short but contains substantive governance content rather than a mere announcement. Therefore, the classification is CGR with high confidence.
2025-04-23 Chinese
关于提请股东大会授权董事会办理以简易程序向特定对象发行股票的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding a proposal to the shareholders' meeting to authorize the board of directors to handle a simplified procedure for a private placement of shares to specific investors. It details the terms of the proposed share issuance, including the type of shares, pricing, lock-up period, use of proceeds, and authorization scope for the board. The document is a formal announcement of a capital raising plan requiring shareholder approval, not a report containing financial statements or results. It is not a full financing update with results but an announcement of a capital/financing activity proposal. Therefore, the document fits best under the category Capital/Financing Update (CAP). The document length is 3328 characters, which is consistent with an announcement rather than a full report.
2025-04-23 Chinese
关于2024年度募集资金存放和使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024年度募集资金存放和使用情况专项报告" which translates to a "Special Report on the Deposit and Use of Raised Funds for the Year 2024." It details the amount of funds raised, their deposit, usage, management, and specific investment projects related to the raised capital. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding the management and use of raised funds. The document includes detailed tables on the use of funds, project progress, and approvals from board meetings. It is a comprehensive report focused on the management and use of capital raised by the company, not a general annual report or earnings release. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is substantive and over 11,000 characters, so it is not merely an announcement of a report. Therefore, the correct classification is CAP with high confidence.
2025-04-23 Chinese
关于选举公司第四届董事会董事长、专门委员会委员及聘任公司高级管理人员的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding the election of the company's fourth board chairman, members of specialized committees, and the appointment of senior management personnel. It includes detailed information about the individuals appointed, their qualifications, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in the company's board of directors and senior management appointments. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 5858 characters, which is sufficient for a detailed announcement rather than a brief notice or report publication announcement.
2025-04-23 Chinese
2024年度独立董事述职报告 （尤启冬）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2024 by an independent director of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the director's duties, attendance at board meetings, communication with auditors, supervision of financial reporting, and other governance-related activities. It does not contain financial statements or detailed financial data but rather focuses on the director's role, governance, and oversight activities. This type of document is a report on board/management information, specifically about the independent director's duties and activities during the year. It is not an annual report, audit report, or earnings release. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters but contains substantive content, not just an announcement or certification, so it is not RPA or RNS.
2025-04-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.